Rituximab [Truxima®]

[SDL] Rituximab Biosimilar (Truxima) Concentrate For Solution For Infusion 100 mg/10 mL, 500 mg/50 mL

[MSHL] Rituximab biosimilar Concentrate For Solution For Infusion 100 mg/10 mL, 500 mg/50 mL

1. For cancer treatment.

[MSHL] Rituximab Concentrate For Solution For Infusion 100 mg/10 mL, 500 mg/50 mL

1. Ibrutinib in combination with rituximab for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

2. Ibrutinib in combination with rituximab, for the treatment of Waldenstrom’s Macroglobulinaemia.

[MSHL] Rituximab biosimilar Concentrate For Solution For Infusion 100 mg/10 mL, 500 mg/50 mL

1. Venetoclax in combination with rituximab biosimilar (subsidised brand) for patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. Maximum treatment duration of rituximab is 6 cycles and venetoclax is 24 months.

[MSHL] Rituximab biosimilar Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL

1. Polatuzumab in combination with rituximab biosimilar (subsidised brand), cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma (DLBCL) in patients with an international prognostic index (IPI) score of 3 to 5.

[MSHL] Rituximab Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL

1. Polatuzumab in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma (DLBCL).

View legend

01/07/2022 Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis

The Ministry of Health’s Drug Advisory Committee has recommended:

• Baricitinib 2 mg and 4 mg tablets for treating adults with moderately to severely active rheumatoid arthritis;

• Tofacitinib 5 mg tablet for treating adults with moderately to severely active rheumatoid arthritis; and

• Rituximab biosimilar (Truxima) 500 mg concentrate for infusion for treating adults with severely active rheumatoid arthritis

in line with their registered indications.

Subsidy status

[R] Baricitinib 2 mg and 4 mg tablets and tofacitinib 5 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

[R] Baricitinib and tofacitinib should be used in line with the clinical criteria in the MAF checklist for initial and continuing prescriptions for patients with rheumatoid arthritis.

[R] Rituximab biosimilar (Truxima) 500 mg concentrate for infusion is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication.

[NR] SDL subsidy and MAF assistance does not apply to any formulations or strengths of tocilizumab, rituximab reference biologic (MabThera) or other rituximab biosimilars (such as Rixathon).

18/01/2021 Rituximab for treating non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia

The Ministry of Health’s Drug Advisory Committee has recommended:

• Rituximab biosimilar (Truxima) 100 mg/10 ml and 500 mg/50 ml concentrate for infusion for treating:

  • CD20-positive diffuse large B-cell non-Hodgkin’s lymphoma,

  • Indolent B-cell non-Hodgkin’s lymphomas,

  • Stage III-IV follicular lymphoma, or

  • CD20-positive chronic lymphocytic leukaemia

  in line with its registered indications; and

• The removal of rituximab reference biologic 100 mg/10 ml and 500 mg/50 ml concentrate for infusion (MabThera) from the Medication Assistance Fund (MAF) for all indications.

Subsidy status

[R] Truxima 100 mg/10 ml and 500 mg/50 ml concentrate for infusion is recommended for inclusion in the MOH Standard Drug List (SDL) for the abovementioned indications from 18 January 2021. The MAF listing of MabThera will cease on 19 July 2021.

[NR] SDL subsidy does not apply to any other rituximab biosimilars (such as Rixathon), or to any formulations or strengths of MabThera.

View legend

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration